MCID: ACT135
MIFTS: 52

Acute Graft Versus Host Disease

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Acute Graft Versus Host Disease

MalaCards integrated aliases for Acute Graft Versus Host Disease:

Name: Acute Graft Versus Host Disease 52 58
Acute Graft-Versus-Host Disease 54
Acute Gvh Disease 71
Acute Gvhd 52

Classifications:

Orphanet: 58  
Rare immunological diseases


External Ids:

ICD10 via Orphanet 33 T86.0
UMLS via Orphanet 72 C0856825
Orphanet 58 ORPHA99920
UMLS 71 C0856825

Summaries for Acute Graft Versus Host Disease

MalaCards based summary : Acute Graft Versus Host Disease, also known as acute graft-versus-host disease, is related to chronic graft versus host disease and graft-versus-host disease. An important gene associated with Acute Graft Versus Host Disease is ARHGAP45 (Rho GTPase Activating Protein 45), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lomustine and Panobinostat have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Increased viability with MLN4924 (a NAE inhibitor)

Related Diseases for Acute Graft Versus Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Acute Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 549)
# Related Disease Score Top Affiliating Genes
1 chronic graft versus host disease 31.4 IL2RA IL10 IFNG
2 graft-versus-host disease 31.3 TNF IL2 IL10 IFNG FASLG ARHGAP45
3 post-transplant lymphoproliferative disease 31.0 TNF IL10
4 mucositis 30.8 IL2 IL10 CSF3
5 bronchiolitis obliterans 30.6 TNF IL10 IFNG
6 exanthem 30.6 TNF IL2 IL10 IFNG CSF3
7 stevens-johnson syndrome/toxic epidermal necrolysis 30.6 IL2 IFNG
8 bronchiolitis 30.5 TNF IL4 IL10 IFNG
9 bronchitis 30.4 TNF IL4 IL10
10 lymphoproliferative syndrome 30.4 IL2RA IL2 IL10 FASLG
11 hypereosinophilic syndrome 30.2 IL4 IL2RA IL2 IL10 IFNG
12 alopecia 30.2 TNF IL4 IL2 IFNG
13 pancytopenia 30.1 IL2RA IFNG CSF3
14 systemic scleroderma 30.1 TNF IL4 IL10 IFNG
15 urticaria 30.1 TNF IL4 IL10
16 pemphigus 30.1 TNF IL4 IL10
17 hemorrhagic cystitis 30.1 TNF IL2 CSF3
18 lymphoma, hodgkin, classic 30.0 IL2RA IL2 CSF3
19 localized scleroderma 30.0 TNF IL4 IL2
20 bacterial sepsis 30.0 TNF IL18 IL10
21 acute pancreatitis 30.0 TNF IL18 IL10
22 cystitis 30.0 TNF IL4 IL2 IL18
23 keratoconjunctivitis 29.9 TNF IL4 IL2 IFNG
24 chickenpox 29.9 TNF IL4 IL2 IL10 IFNG
25 conjunctivitis 29.9 TNF IL4 IL2 IL10 IFNG
26 toxic shock syndrome 29.9 TNF IL4 IL2 IL10 IFNG
27 allergic hypersensitivity disease 29.9 TNF IL4 IL2 IL10 IFNG
28 bacterial pneumonia 29.8 TNF IL10 CSF3
29 skin disease 29.8 TNF IL4 IL2 IL18 IL10 IFNG
30 invasive aspergillosis 29.8 NOD2 IL10 IFNG CSF3
31 erythema multiforme 29.8 TNF IL4 IL2 IFNG FASLG
32 b cell deficiency 29.8 TNF IL4 IL2 IL10
33 proteasome-associated autoinflammatory syndrome 1 29.8 TNF IL4 IL18 IL10 IFNG
34 neutropenia 29.7 TNF IL2 IL10 IFNG FASLG CSF3
35 diarrhea 29.7 TNF NOD2 IL2 IL10 IFNG CSF3
36 myelodysplastic syndrome 29.7 TNF IL2 IL10 IFNG FASLG CSF3
37 lichen planus 29.7 TNF IL4 IL2 IL10 IFNG
38 bacterial infectious disease 29.5 TNF NOD2 IL18 IL10 IFNG CSF3
39 lymphoma 29.5 IL4 IL2RA IL2 IL10 CSF3
40 cutaneous t cell lymphoma 29.4 IL4 IL2RB IL2RA IL2 IFNG
41 severe combined immunodeficiency 29.4 IL4 IL2RB IL2RA IL2 IL10 IFNG
42 thyroiditis 29.4 TNF IL4 IL2 IL10 FASLG
43 leukemia, acute myeloid 29.4 TNF IL4 IL2 IL10 IFNG FASLG
44 ulcerative colitis 29.4 TNF NOD2 IL4 IL2 IL10 IFNG
45 diphtheria 29.4 TNF IL4 IL2RB IL2RA IL2 IFNG
46 gastroenteritis 29.3 TNF IL4 IL10 IFNG CSF3
47 primary biliary cirrhosis 29.2 TNF IL4 IL2RB IL2 IL10 IFNG
48 lung disease 29.1 TNF IL4 IL18 IL10 IFNG CSF3
49 stomatitis 29.0 TNF IL4 IL2 IL10 IFNG CSF3
50 hematologic cancer 28.9 TNF IL2RA IL2 CSF3 ARHGAP45

Graphical network of the top 20 diseases related to Acute Graft Versus Host Disease:



Diseases related to Acute Graft Versus Host Disease

Symptoms & Phenotypes for Acute Graft Versus Host Disease

GenomeRNAi Phenotypes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.61 IL2 NOD2
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.61 FASLG IL10 IL18 IL2 IL2RA NOD2
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 IL10 IL18 IL2RA TNF
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 IL10 IL18 IL2 IL2RA NOD2 TNF

MGI Mouse Phenotypes related to Acute Graft Versus Host Disease:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 CSF3 FASLG IFNG IL10 IL18 IL2
2 digestive/alimentary MP:0005381 10.19 FASLG IFNG IL10 IL18 IL2 IL2RA
3 cellular MP:0005384 10.16 FASLG IFNG IL10 IL18 IL2 IL4
4 growth/size/body region MP:0005378 10.16 IFNG IL10 IL18 IL2 IL2RA IL2RB
5 immune system MP:0005387 10.15 CSF3 FASLG IFNG IL10 IL18 IL2
6 homeostasis/metabolism MP:0005376 10.1 FASLG IFNG IL10 IL18 IL2 IL2RA
7 endocrine/exocrine gland MP:0005379 10.08 FASLG IFNG IL10 IL2 IL2RA IL2RB
8 integument MP:0010771 9.97 CSF3 FASLG IFNG IL10 IL18 IL2RB
9 mortality/aging MP:0010768 9.9 FASLG IFNG IL10 IL18 IL2 IL2RA
10 liver/biliary system MP:0005370 9.86 FASLG IFNG IL10 IL2 IL2RB IL4
11 respiratory system MP:0005388 9.56 FASLG IFNG IL10 IL2 IL2RA IL4
12 vision/eye MP:0005391 9.23 FASLG IFNG IL10 IL18 IL2 IL2RA

Drugs & Therapeutics for Acute Graft Versus Host Disease

Drugs for Acute Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 298)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
2
Panobinostat Approved, Investigational Phase 4 404950-80-7 6918837
3
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
6
Mycophenolic acid Approved Phase 4 24280-93-1 446541
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
10
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
11
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
12
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
13
Semustine Experimental, Investigational Phase 4 13909-09-6
14 Immunosuppressive Agents Phase 4
15 Immunologic Factors Phase 4
16 Histone Deacetylase Inhibitors Phase 4
17 Calcium, Dietary Phase 4
18 Vitamins Phase 4
19 Calciferol Phase 4
20 Micronutrients Phase 4
21 Trace Elements Phase 4
22 Nutrients Phase 4
23 Ergocalciferols Phase 4
24 Hydroxycholecalciferols Phase 4
25 Vitamin D2 Phase 4
26 Hormones Phase 4
27 Hormone Antagonists Phase 4
28 glucocorticoids Phase 4
29 Anti-Infective Agents Phase 4
30 Antifungal Agents Phase 4
31 Pharmaceutical Solutions Phase 4
32 Cytochrome P-450 Enzyme Inhibitors Phase 4
33 Cytochrome P-450 CYP3A Inhibitors Phase 4
34
Hydroxyitraconazole Phase 4
35
Calcium Nutraceutical Phase 4 7440-70-2 271
36
Peginterferon alfa-2b Approved Phase 2, Phase 3 99210-65-8, 215647-85-1
37
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
38
leucovorin Approved Phase 3 58-05-9 6006 143
39
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
40
Lenograstim Approved, Investigational Phase 3 135968-09-1
41
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
42
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
43
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
44
Mesna Approved, Investigational Phase 3 3375-50-6 598
45
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
46
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
47
Voriconazole Approved Phase 3 137234-62-9 71616
48
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
49
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
50
Pegaspargase Approved, Investigational Phase 3 130167-69-0

Interventional clinical trials:

(show top 50) (show all 587)
# Name Status NCT ID Phase Drugs
1 Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Unknown status NCT02677181 Phase 4 ATG;CsA;mycophenolate mofetil;Methotrexate
2 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
3 Anti-thymocyte Globulins for GVHD Prophylaxis After HLA-matched Sibling Stem Cell Transplantation in Patients at 40 Years of Age or More With Hematological Malignancies Unknown status NCT01856803 Phase 4 anti thymoglobulin
4 Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors Completed NCT02412423 Phase 4 post-transplantation cyclophosphamide
5 Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
6 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
7 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
8 A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil;Ciclosporin A (CsA);methotrexate (MTX)
9 Shanghai General Hospital Affiliated to Shanghai Jiao Tong University Recruiting NCT03608059 Phase 4 ATG/PTCy;standard ATG;standard PTCy
10 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
11 Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies Recruiting NCT02386800 Phase 4 ruxolitinib tablets or oral pediatric formulation, panobinostat capsules;ruxolitinib tablets or oral pediatric formulation
12 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
13 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Enrolling by invitation NCT03176849 Phase 4
14 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Not yet recruiting NCT03190733 Phase 4 ATG
15 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
16 Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
17 Extracorporeal Photopheresis for Steroid-refractory Acute GVHD in Children and Young Adults: a Safety and Feasibility Study. Unknown status NCT00179855 Phase 2, Phase 3
18 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
19 Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
20 The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
21 Multi-Centre Prospective Randomized Study on the Use of Two Different Doses of Rabbit Anti-Thymocyte Globulin for GVHD Prevention in Paediatric Patients With Haematological Malignancies Given an Unrelated Donor Haematopoietic Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
22 A Phase III Study to Determine Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease Completed NCT00929695 Phase 3 prednisone;methylprednisolone
23 A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease Completed NCT00035880 Phase 2, Phase 3 ABX-CBL
24 Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD Completed NCT02652130 Phase 3
25 A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD Completed NCT02336230 Phase 3 remestemcel-L
26 A Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal™ (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD Completed NCT00366145 Phase 3 Standard of Care for GVHD
27 The Use of Etanercept (Enbrel) as Sole Treatment for Grade I Acute Graft Versus Host Disease Completed NCT00726375 Phase 3 Etanercept (Enbrel)
28 Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease Completed NCT00002456 Phase 3 cyclosporine;methotrexate
29 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD Completed NCT00562497 Phase 3 Prochymal
30 A Phase III, Randomized, Multicentre Trial Comparing Allogeneic Filgrastim Mobilised Peripheral Blood Progenitor Cell Transplantation (PBPCT) With Allogeneic Bone Marrow Transplantation (BMT) in Patients With Acute Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT01020175 Phase 3
31 Treatment of Acute Graft vs. Host Disease With Steroids Plus Daclizumab (Zenapax) or Placebo Completed NCT00053976 Phase 3 methylprednisolone;Placebo
32 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
33 A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
34 A Prospective Randomized Study Comparing Rapamune and Tacrolimus vs. Cyclosporine and Methotrexate as Immune Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation, Using HLA-A, -B, -DRβ1 Identical Related or Unrelated Donors. A Nordic Multicenter Study. Completed NCT00993343 Phase 3 Sirolimus/tacrolimus;cyclosporine/methotrexate
35 Nonmyeloablative Allogeneic Stem Cell Transplantation in Elderly Patients With Hematological Malignancies:Results From the GITMO (Gruppo Italiano Trapianto Midollo Osseo)Multicenter Prospective Clinical Trial Completed NCT00382759 Phase 2, Phase 3
36 Hematopoietic Stem Cell Transplantation Using Matched Unrelated Donor Peripheral Blood or Bone Marrow for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
37 A Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Thymoglobuline in Non-myeloablative Allogeneic Hemapoietic Stem-cell Transplantation (NST) Completed NCT00130754 Phase 3 Thymoglobuline
38 GvHD Prophylaxis With ATG-Fresenius S in Allogeneic Stem Cell Transplantation From Matched Unrelated Donors: A Randomized Phase III Multicenter Trial Comparing a Standard GvHD Prophylaxis With Cyclosporine A and Methotrexate With Additional Pretransplant ATG-Fresenius S Completed NCT00655343 Phase 3 ATG-Fresenius S
39 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
40 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
41 T-Cell Depletion in Unrelated Donor Marrow Transplantation Completed NCT00000591 Phase 3
42 Haploidentical Stem Cell Transplantation Utilizing Purified CD34+ Hematopoietic Cells for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
43 A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant Recruiting NCT04167514 Phase 3 Placebo
44 Treatment of Steroid-resistant Severe Acute Graft-versus-host Disease With Mesenchymal Stem Cells Recruiting NCT03631589 Phase 2, Phase 3
45 Induction of Graft Versus Tumor Effect of Pegylated Interferon Alpha-2b for Patients With Relapsed Hematological Malignancies After Allogeneic Stem Cell Transplantation Recruiting NCT02634294 Phase 2, Phase 3 Peg interferon alfa-2b
46 The Effectiveness of Lactobacillus Plantarum (LBP) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT) Recruiting NCT03057054 Phase 3
47 A Multi-center Randomized in Double-blinded Phase III Study Comparing Standard Care Therapy Alone Versus Corticosteroids and Low-dose Methotrexate (MTX) for the First-line Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Recruiting NCT03371667 Phase 3 Methotrexate;Placebo
48 Total Body Irradiation Dose De-escalation Study in Patients With Fanconi Anemia Undergoing Alternate Donor Hematopoietic Cell Transplantation Recruiting NCT00352976 Phase 2, Phase 3 Cyclophosphamide;Fludarabine;Mycophenolate Mofetil;Sirolimus
49 Fecal Microbiota Transplantation in Patients With Acute Gastrointestinal Graft-versus-host-disease After Allogeneic Stem Cell Transplantation Recruiting NCT03819803 Phase 3
50 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT03657160 Phase 3 Vedolizumab;Vedolizumab Placebo

Search NIH Clinical Center for Acute Graft Versus Host Disease

Genetic Tests for Acute Graft Versus Host Disease

Anatomical Context for Acute Graft Versus Host Disease

MalaCards organs/tissues related to Acute Graft Versus Host Disease:

40
Bone, Bone Marrow, T Cells, Myeloid, Skin, B Cells, Liver

Publications for Acute Graft Versus Host Disease

Articles related to Acute Graft Versus Host Disease:

(show top 50) (show all 8541)
# Title Authors PMID Year
1
Investigation of functional IL-10 gene polymorphism and IL-10 levels in acute graft-versus-host disease. 61 54
20195716 2010
2
[Correlation of donor and recipient serum interleukin 2 and tumor necrosis factor alpha levels to acute graft-versus-host disease in hematopoietic stem cell transplantation]. 54 61
20423859 2010
3
A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. 61 54
19896079 2009
4
Granulocyte colony-stimulating factor-induced immature myeloid cells inhibit acute graft-versus-host disease lethality through an indoleamine dioxygenase-independent mechanism. 54 61
19740324 2009
5
Acute graft-versus-host disease after liver transplant: novel use of etanercept and the role of tumor necrosis factor alpha inhibitors. 61 54
19326415 2009
6
Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation. 61 54
18081874 2009
7
IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation. 61 54
19295315 2009
8
Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells. 54 61
18721759 2008
9
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. 61 54
18541197 2008
10
Induction of NKG2D ligands by gamma radiation and tumor necrosis factor-alpha may participate in the tissue damage during acute graft-versus-host disease. 54 61
18360276 2008
11
[A comparison of clinical outcomes between unrelated donor and HLA-haploidentical donor hematopoietic stem cell transplantation]. 61 54
18681306 2008
12
[Establishment of an xenogeneic acute graft-versus-host disease model in NOD/SCID mice by engraftment of G-CSF mobilized human mononuclear cells]. 54 61
18681307 2008
13
Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. 61 54
17827036 2008
14
[Effect of granulocyte colony-stimulating factor on immunological regulation and its application in allogenic hematopoietic stem cell transplantation]. 61 54
17956704 2007
15
Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease. 54 61
17465640 2007
16
[Changes of IL-2, IL-8, IL-10 and TNF-alpha levels in sera of patients with acute graft-versus-host disease]. 54 61
16928315 2006
17
Costs of allogeneic hematopoietic stem cell transplantation. 54 61
16858272 2006
18
Successful reduced-intensity stem cell transplantation in a patient with myelodysplastic syndrome combined with Sweet's syndrome. 54 61
17325958 2006
19
Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. 54 61
16699531 2006
20
Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. 61 54
16565744 2006
21
[Influence of G-CSF mobilization on functions of donor T lymphocyte subpopulation and acute graft-versus-host disease]. 61 54
16584603 2006
22
Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. 61 54
16436969 2006
23
Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. 54 61
16431290 2006
24
KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. 54 61
16131567 2005
25
Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. 54 61
16109775 2005
26
Limiting dilution analysis of interleukin-2 producing helper T-cell frequencies as a tool in allogeneic hematopoietic cell transplantation. 54 61
16177628 2005
27
Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. 54 61
16125640 2005
28
Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. 61 54
16125638 2005
29
Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. 54 61
16210965 2005
30
Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. 54 61
16098072 2005
31
NK-KIR transcript kinetics correlate with acute graft-versus-host disease occurrence after allogeneic bone marrow transplantation. 54 61
15935882 2005
32
Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. 61 54
15744237 2005
33
Hyperuricemia and bone marrow transplantation. 61 54
15604610 2005
34
Genetic polymorphisms predicting the outcome of bone marrow transplants. 54 61
15566351 2004
35
Interleukin-18: recent advances. 54 61
15548995 2004
36
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. 54 61
15548717 2004
37
Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. 54 61
15280194 2004
38
Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. 54 61
15449032 2004
39
Patient interleukin-18 GCG haplotype associates with improved survival and decreased transplant-related mortality after unrelated-donor bone marrow transplantation. 54 61
15327523 2004
40
Lack of IFN-gamma 2/2 homozygous genotype independently of recipient age and intensity of conditioning regimen influences the risk of aGVHD manifestation after HLA-matched sibling haematopoietic stem cell transplantation. 61 54
15235581 2004
41
Polymorphisms within the genes encoding TNF-alpha and TNF-beta associate with the incidence of post-transplant complications in recipients of allogeneic hematopoietic stem cell transplants. 61 54
15467488 2004
42
Cytokine production during myeloablative and reduced intensity therapy before allogeneic stem cell transplantation. 61 54
15194539 2004
43
Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. 61 54
14691124 2004
44
Elevated serum interleukin-15 level in acute graft-versus-host disease after hematopoietic cell transplantation. 54 61
14663280 2003
45
G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune diseases. 61 54
12676791 2003
46
Roles of interleukin-10 in acute graft-versus-host disease and graft rejection. 61 54
12875717 2003
47
Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. 61 54
12433681 2003
48
TIP, a T-cell factor identified using high-throughput screening increases survival in a graft-versus-host disease model. 54 61
12598909 2003
49
Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. 54 61
12476283 2002
50
Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. 61 54
12393699 2002

Variations for Acute Graft Versus Host Disease

Expression for Acute Graft Versus Host Disease

Search GEO for disease gene expression data for Acute Graft Versus Host Disease.

Pathways for Acute Graft Versus Host Disease

Pathways related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 TNFRSF4 TNF NOD2 IL4 IL2RB IL2RA
2
Show member pathways
13.83 TNFRSF4 TNF IL4 IL2RB IL2RA IL2
3
Show member pathways
13.67 TNFRSF4 TNF IL4 IL2RB IL2RA IL2
4
Show member pathways
13.54 TNF IL4 IL2RB IL2RA IL2 IL18
5
Show member pathways
13.43 TNFRSF4 TNF IL4 IL2RB IL2RA IL2
6
Show member pathways
13.31 TNFRSF4 TNF IL4 IL2RB IL2RA IL2
7
Show member pathways
13.26 TNFRSF4 TNF NOD2 IL4 IL2RB IL2RA
8
Show member pathways
13.19 TNF IL4 IL2RB IL2RA IL2 IFNG
9
Show member pathways
13.04 TNF IL4 IL2RB IL2RA IL2 FASLG
10
Show member pathways
13.02 TNF IL2 IL10 IFNG FASLG
11
Show member pathways
12.93 TNF IL4 IL2RA IL2 IL10 IFNG
12
Show member pathways
12.89 TNF IL2RB IL2RA IL2 IL18 IFNG
13 12.88 IL4 IL2RB IL2RA IL2 IFNG FASLG
14
Show member pathways
12.79 TNF IL4 IL2RB IL2RA IL2
15
Show member pathways
12.72 TNF IL4 IL2RA IL2 IL18 IL10
16
Show member pathways
12.65 TNF NOD2 IL4 IL2RB IL2RA IL2
17
Show member pathways
12.64 TNF IL4 IL2 IL10 IFNG
18
Show member pathways
12.62 TNF IL2 IL18 IL10 IFNG
19 12.6 TNFRSF4 TNF IL4 IL2RB IL2RA IL2
20
Show member pathways
12.56 TNF IL4 IL2 IFNG FASLG
21
Show member pathways
12.55 IL4 IL2RB IL2RA IL2 IL10 IFNG
22
Show member pathways
12.43 TNF IL2RB IL2RA IL2 IL18 IL10
23 12.36 TNF IL2RB IL2RA IL2
24
Show member pathways
12.35 TNF IL4 IFNG CSF3
25
Show member pathways
12.35 TNF IL4 IL2 IFNG
26
Show member pathways
12.35 TNF IL4 IL2RA IL2 IL18 IL10
27 12.32 TNF NOD2 IL18 IL10 IFNG
28
Show member pathways
12.29 TNF IL4 IL10 IFNG
29
Show member pathways
12.22 TNF IL4 IFNG FASLG
30
Show member pathways
12.2 IL4 IL2RB IL2RA IL2
31
Show member pathways
12.13 IL2RB IL2RA IL2 IFNG
32 12.11 TNF IL4 IL18 IL10 FASLG
33 12.07 TNF IL2 IL18 IL10
34 12.07 TNF IL4 IL2 IFNG
35
Show member pathways
12.07 IL4 IL2RB IL2RA IL2 IL18 IFNG
36
Show member pathways
12.06 TNF IL2 IL18 IL10 IFNG
37 11.98 TNF IL4 IL2RA CSF3
38 11.92 TNF IL10 IFNG
39 11.92 TNF IL4 IL2RB IL2RA IL2 IL10
40 11.88 TNF IL18 IFNG
41 11.85 TNF IL2 IL10 IFNG
42
Show member pathways
11.85 TNF IL4 IL2RA IL2 IFNG FASLG
43
Show member pathways
11.84 IL4 IL2RB IL2RA IL2 FASLG
44
Show member pathways
11.82 TNFRSF4 TNF FASLG
45 11.82 IL4 IL2 IFNG
46
Show member pathways
11.7 TNF IL2 IFNG
47 11.7 TNF IL4 CSF3
48 11.67 TNF IL2 IFNG FASLG
49 11.67 TNF IL18 IL10 IFNG CSF3
50 11.66 TNF IL4 IL18 IL10 CSF3

GO Terms for Acute Graft Versus Host Disease

Cellular components related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 TNF IL4 IL2 IL18 IL10 IFNG
2 external side of plasma membrane GO:0009897 9.72 TNFRSF4 TNF IL2RB IL2RA FASLG
3 cell surface GO:0009986 9.43 TNFRSF4 TNF NOD2 IL2RB IL2RA FASLG
4 extracellular region GO:0005576 9.28 TNF IL4 IL2 IL18 IL10 IFNG
5 interleukin-2 receptor complex GO:0005893 9.16 IL2RB IL2RA

Biological processes related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.25 IL4 IL2RB IL18 IL10 FASLG CSF3
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 TNF NOD2 IL4 IL2 IL18 IL10
3 inflammatory response GO:0006954 10.02 TNFRSF4 TNF IL2RA IL18
4 positive regulation of cell proliferation GO:0008284 9.97 NOD2 IL4 IL2 IFNG FASLG CSF3
5 cellular response to lipopolysaccharide GO:0071222 9.93 TNF NOD2 IL10 CSF3
6 MAPK cascade GO:0000165 9.91 TNF IL2RB IL2RA IL2 IL18
7 tumor necrosis factor-mediated signaling pathway GO:0033209 9.89 TNFRSF4 TNF FASLG
8 positive regulation of DNA-binding transcription factor activity GO:0051091 9.89 TNF IL10 CSF3
9 negative regulation of inflammatory response GO:0050728 9.88 IL4 IL2RA IL2 IL10
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.87 TNF IL18 CSF3
11 cellular response to organic cyclic compound GO:0071407 9.85 TNF NOD2 IL18
12 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.84 TNF NOD2 IL18
13 positive regulation of T cell proliferation GO:0042102 9.83 IL4 IL2RA IL2
14 positive regulation of phagocytosis GO:0050766 9.81 TNF IL2RB IFNG
15 positive regulation of interferon-gamma production GO:0032729 9.81 TNF IL2 IL18
16 extrinsic apoptotic signaling pathway GO:0097191 9.8 TNF IFNG FASLG
17 positive regulation of B cell proliferation GO:0030890 9.79 TNFRSF4 IL4 IL2
18 positive regulation of inflammatory response GO:0050729 9.78 TNF IL2 IL18 IFNG
19 positive regulation of cytokine secretion GO:0050715 9.75 TNF IL10 IFNG
20 positive regulation of amyloid-beta formation GO:1902004 9.72 TNF IFNG
21 astrocyte activation GO:0048143 9.72 TNF IFNG
22 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.72 TNF IFNG
23 microglial cell activation GO:0001774 9.72 TNF IL4 IFNG
24 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 TNF IL10
25 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.71 NOD2 IFNG
26 positive regulation of neuroinflammatory response GO:0150078 9.71 TNF IL18
27 positive regulation of activated T cell proliferation GO:0042104 9.71 IL2RA IL2 IL18
28 positive regulation of immunoglobulin secretion GO:0051024 9.7 TNFRSF4 IL2
29 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.7 IL4 IL10
30 negative regulation of amyloid-beta clearance GO:1900222 9.7 TNF IFNG
31 positive regulation of isotype switching to IgG isotypes GO:0048304 9.7 IL4 IL2
32 positive regulation of T cell differentiation GO:0045582 9.7 IL4 IL2RA IL2
33 negative regulation of T-helper 17 cell differentiation GO:2000320 9.69 IL4 IL2
34 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.69 TNF IFNG
35 necroptotic signaling pathway GO:0097527 9.68 TNF FASLG
36 endothelial cell apoptotic process GO:0072577 9.68 TNF IL10
37 positive regulation of mononuclear cell migration GO:0071677 9.68 TNF IL4
38 negative regulation of lymphocyte proliferation GO:0050672 9.67 IL2RA IL2
39 positive regulation of tissue remodeling GO:0034105 9.67 IL2 IL18
40 negative regulation of cytokine production involved in immune response GO:0002719 9.67 TNF IL10
41 positive regulation of cellular respiration GO:1901857 9.65 IL4 IFNG
42 neuroinflammatory response GO:0150076 9.65 IL4 IFNG
43 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 TNF IL10
44 regulation of isotype switching GO:0045191 9.64 IL4 IL10
45 regulation of regulatory T cell differentiation GO:0045589 9.63 IL2RA IL2 IFNG
46 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IFNG
47 regulation of T cell homeostatic proliferation GO:0046013 9.61 IL2RA IL2
48 positive regulation of interleukin-17 production GO:0032740 9.61 NOD2 IL2 IL18
49 cytokine-mediated signaling pathway GO:0019221 9.61 TNF IL4 IL2RB IL2RA IL2 IL18
50 receptor biosynthetic process GO:0032800 9.6 TNF IL10

Molecular functions related to Acute Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL4 IL2 IL10 CSF3
2 interleukin-2 binding GO:0019976 9.26 IL2RB IL2RA
3 cytokine activity GO:0005125 9.23 TNF IL4 IL2 IL18 IL10 IFNG
4 interleukin-2 receptor activity GO:0004911 8.96 IL2RB IL2RA

Sources for Acute Graft Versus Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....